Rituximab, Lenalidomide, and Nivolumab in Treating Participants With Relapsed or Refractory Non-Germinal Center Type Diffuse Large B Cell Lymphoma or Primary Central Nervous System Lymphoma

• Status: Terminated
• Trial end date: 2019-04-16

Summary

This phase I/II trial studies the side effects and best dose of lenalidomide when given in combination with rituximab and nivolumab and how well they work in treating participants with non-germinal center type diffuse large B cell lymphoma or primary central nervous system lymphoma that has come back or isn't responding to treatment. Monoclonal antibodies, such as rituximab and nivolumab, may interfere with ability of cancer cells to grow and spread. Drugs used in chemotherapy, such as lenalidomide, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving rituximab, lenalidomide, and nivolumab may work better in treating participants with diffuse large B cell lymphoma.

• Phase: Phase 1

Details

• Lead Sponsor: Vanderbilt-Ingram Cancer Center
• Collaborators: Bristol-Myers Squibb; National Cancer Institute (NCI)
• Treatments: Antibodies, Monoclonal; Lenalidomide; Nivolumab; Rituximab; Thalidomide